Full history for every metric is available with a Kvantra account
Stealth BioTherapeutics Corp (MITO)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 21 | 0 | 0 | 0 |
| Operating profit | $m | -51 | -48 | |||||
| Net profit | $m | -61 | -83 | -97 | -72 | -57 | -54 | -54 |
| EPS reported | $ | -1.16 | -0.95 | |||||
| Operating cashflow per share | $ | -0.97 | -0.97 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.97 | -0.97 | |||||
| Free cash flow | $m | -45 | -35 | |||||
| Net debt | $m | -33 | -20 | |||||
| Book value equity | $m | -45 | -52 | |||||
| Book value per share | $ | -0.98 | -0.88 | |||||
| Number of shares | m | 46.35 | 59.62 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.85 | -0.33 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.85 | 0.00 | |||||
| EV/EBITDA LTM | x | -0.10 | 0.65 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -139.77% | -362.54% | |||||
| FCF Yield | % | -117.08% | - | |||||
| Quality | ||||||||
| ROE | % | 118.71% | 193.18% | |||||
| ROIC | % | -130.17% | -130.17% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.30 | -2.56 | |||||
| Net Debt/EBITDA | x | 0.65 | 0.65 | |||||
| EBIT/Net interest | x | -41.29 | -41.29 | |||||
| Net debt/market cap | % | -87.03% | - | |||||
| Net debt/Equity | x | 0.74 | 0.38 | |||||
| Gross debt/equity | x | -0.30 | -0.26 | |||||
Company overview
Stealth BioTherapeutics Corp is a clinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market treatments for illnesses arising from mitochondrial dysfunction. Its primary therapeutic candidate, Elamipretide, is currently progressing through multiple clinical stages: a Phase 3 trial for Barth Syndrome and replisome myopathies; a Phase 2/3 study for Duchenne cardiomyopathy; a Phase 2a investigation for Friedreich's ataxia; and Phase 2 trials for both dry age-related macular degeneration and Leber's hereditary optic neuropathy. The company's developmental pipeline further includes SBT-20, designed to address complications associated with diabetes, various renal and ocular conditions, and several neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's, and ALS. Additionally, SBT-550 is being evaluated for rare neurological indications, while SBT-272, a peptidomimetic, is engineered to target and enhance mitochondrial function amidst oxidative stress. Established in 2006, Stealth BioTherapeutics Corp operates from its base in George Town, Cayman Islands.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Stealth BioTherapeutics Corp (MITO)
Stealth BioTherapeutics Corp is a clinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market treatments for illnesses arising from mitochondrial dysfunction. Its primary therapeutic candidate, Elamipretide, is currently progressing through multiple clinical stages: a Phase 3 trial for Barth Syndrome and replisome myopathies; a Phase 2/3 study for Duchenne cardiomyopathy; a Phase 2a investigation for Friedreich's ataxia; and Phase 2 trials for both dry age-related macular degeneration and Leber's hereditary optic neuropathy. The company's developmental pipeline further includes SBT-20, designed to address complications associated with diabetes, various renal and ocular conditions, and several neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's, and ALS. Additionally, SBT-550 is being evaluated for rare neurological indications, while SBT-272, a peptidomimetic, is engineered to target and enhance mitochondrial function amidst oxidative stress. Established in 2006, Stealth BioTherapeutics Corp operates from its base in George Town, Cayman Islands.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free